Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myelomaDavid G Coffey, Keren Osman, Adolfo Aleman, Selma Bekri, Simone Kats, Amishi Dhadwal, Donna Catamero, Seunghee Kim-Schulze, Sacha Gnjatic, Ajai Chari, Samir Parekh, Sundar Jagannath, Hearn Jay Cho
12 April 2024
Respiratory complex I regulates dendritic cell maturation in explant model of human tumor immune microenvironmentRita Turpin, Ruixian Liu, Pauliina M Munne, Aino Peura, Jenna H Rannikko, Gino Philips, Bram Boeckx, Natasha Salmelin, Elina Hurskainen, Ilida Suleymanova, July Aung, Elisa M Vuorinen, Laura Lehtinen, Minna Mutka, Panu E KovanenSee the full list of authors
11 April 2024
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F Mcdermott, Mehmet A Bilen, Mark Stein, Jeffrey Sosman, Robert Alter, Elizabeth R Plimack, Moshe C Ornstein, Michael Hurwitz, David J Peace, David Einstein, Paul J Catalano, Hans HammersSee the full list of authors
11 April 2024
Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLCNikolaus John, Verena Schlintl, Teresa Sassmann, Jörg Lindenmann, Melanie Fediuk, Robert Wurm, Philipp Douschan, Martin Zacharias, Lipika Kalson, Florian Posch, Gudrun Absenger, Luka Brcic, Philipp J Jost, Angelika Terbuch
11 April 2024
Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeuticsYee Peng Phoon, Jared E Lopes, Lukas W Pfannenstiel, Claudia Marcela Diaz-Montero, Ye F Tian, Marc S Ernstoff, Pauline Funchain, Jennifer S Ko, Raymond Winquist, Heather C Losey, Jan Joseph Melenhorst, Brian R Gastman
11 April 2024
Therapeutic inhibition of monocyte recruitment prevents checkpoint inhibitor-induced hepatitisCathrin L C Gudd, Eoin Mitchell, Stephen R Atkinson, Marie-Anne Mawhin, Samra Turajlic, James Larkin, Mark R Thursz, Robert D Goldin, Nick Powell, Charalambos G Antoniades, Kevin J Woollard, Lucia A Possamai, Evangelos Triantafyllou
4 April 2024
Poor clinical outcomes and immunoevasive contexture in CD161CD8 T cells barren human pancreatic cancerQiangda Chen, Hanlin Yin, Zhenlai Jiang, Taochen He, Yuqi Xie, Weilin Mao, Jiande Han, Siyao Liu, Wenhui Lou, Wenchuan Wu, Joseph R Habib, Jun Yu, Liang Liu, Ning Pu
26 March 2024
Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysisJimmy S Patel, Yena Woo, Amber Draper, Caroline S Jansen, Jennifer W Carlisle, Pasquale F Innominato, Francis A Lévi, Layla Dhabaan, Viraj A Master, Mehmet A Bilen, Mohammad K Khan, Michael C Lowe, Haydn Kissick, Zachary S Buchwald, David C Qian
26 March 2024
Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cellsMaxim Yankelevich, Archana Thakur, Shakeel Modak, Roland Chu, Jeffrey Taub, Alissa Martin, Dana Schalk, Amy Schienshang, Sarah Whitaker, Katie Rea, Daniel W Lee, Qin Liu, Anthony F Shields, Nai-Kong V Cheung, Lawrence G Lum
21 March 2024
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trialDirk Schadendorf, Jason John Luke, Paolo A Ascierto, Georgina V Long, Piotr Rutkowski, Adnan Khattak, Michele Del Vecchio, Luis de la Cruz-Merino, Jacek Mackiewicz, Vanna Chiarion Sileni, John M Kirkwood, Caroline Robert, Jean-Jacques Grob, Reinhard Dummer, Matteo S CarlinoSee the full list of authors
13 March 2024